Senestech Inc Stock Price, News & Analysis

SenesTech (NASDAQ: SNES) has announced that Joshua M. Moss will join its Board of Directors. Moss is the co-founder, Managing Director, and Portfolio Manager at EAM Global Investors, a boutique investment firm managing approximately $3 billion in non-U.S. and emerging market equities.

With over 20 years of institutional investment management experience, Moss previously worked at Credit Suisse in investment banking and equity research, and held senior roles at Allianz Global Investors. At EAM, he has led the firm's growth from inception, launching International Small Cap and Emerging Markets Small Cap strategies.

Moss holds an MBA in Finance from UCLA Anderson School of Management and a BA in History from UC San Diego. He expressed optimism about SenesTech's growth potential, stating that the company has 'the right team and the right product.'

SenesTech (NASDAQ: SNES) announced its Q3 2024 financial results, highlighting record revenue and margin performance. The company reported revenues of $1.4 million for the first nine months of 2024, marking a 51% increase compared to the same period in 2023. Gross margin improved to 65% in Q3 2024 from 49% in Q3 2023, with gross profit dollars increasing by 79%. Operating expenses decreased by 12%, and the adjusted EBITDA loss was the smallest in the company's history, reducing cash burn by 21%.

The launch of Evolve Rat and Evolve Mouse products contributed significantly to revenue, with Evolve Rat accounting for 52% of Q3 2024 revenue and Evolve Mouse 17%. The company expanded its presence on e-commerce platforms like Amazon and Walmart.com, and saw a 20% increase in e-commerce sales. Additionally, SenesTech is negotiating a rat contraception pilot program with New York City and expanding internationally with significant orders from Hong Kong and The Netherlands.

SenesTech (Nasdaq: SNES) announces the launch of its Evolve™ rodent birth control products on Walmart Marketplace. Evolve™ Rat and Evolve™ Mouse represent a non-poisonous approach to rodent control through fertility management. The product is a minimum-risk soft bait that's safe for people, pets, wildlife, and the environment when used as directed. Joel Fruendt, President and CEO, emphasizes that continuous usage can lead to significant population reduction within 2-3 months. This expansion comes as states like California increase restrictions on traditional poisons, creating demand for innovative pest control solutions.

SenesTech (NASDAQ: SNES) has announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after market close. The company will host a conference call at 5:00 pm ET the same day to discuss the results. Interested parties can join via phone at (844) 308-3351 or (412) 317-5407, or through a live webcast available on the company's website. A replay will be accessible for seven days by phone and 90 days via webcast on the company's investor relations page.

SenesTech (Nasdaq: SNES) announces the successful registration of Evolve™ in Hong Kong, introducing a non-lethal rodent birth control solution. The product, distributed exclusively by Fruit Tree , offers an eco-friendly alternative to traditional pest control methods, having earned the 'minimum risk' designation from the U.S. EPA. Evolve™ can reduce fertility in rodent populations by up to 90% when integrated into pest management programs. This development comes as Hong Kong faces a significant rodent problem, with an estimated population of 2.5 million rats and a 39% increase in live rodent captures last year.

SenesTech, Inc. (Nasdaq: SNES), the leader in rodent birth control, announces that the New York City Council has approved a bill to implement a rat contraception pilot program. The bill, Int. No. 736-A, requires the Department of Health and Mental Hygiene (DOHMH) to launch the program within 180 days, in collaboration with the Department of Sanitation (DSNY) and a rodent control expert.

The program will run for at least 12 months in two rat mitigation zones and a comparable area, focusing on residential buildings with waste in containers. SenesTech is currently the only manufacturer of EPA-approved rat contraceptives. The company's President and CEO, Joel Fruendt, expressed readiness to support New York City's pilot program with their product lines ContraPest® and Evolve™.

SenesTech, Inc. (NASDAQ: SNES), the rodent fertility control experts, announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The company, known for inventing the only EPA registered contraceptive for male and female rats, will engage in two key activities:

1. A webcasted presentation at 11:00am ET, accessible via the conference homepage or a direct link. The webcast will be available for replay after the event.

2. Virtual one-on-one meetings with investors throughout the event. Interested parties can arrange meetings through Lytham Partners or by registering on the event website.

This virtual conference provides SenesTech an opportunity to showcase its innovative rodent fertility control solutions to potential investors and industry professionals.

SenesTech (NASDAQ: SNES), the rodent fertility control experts, announced the closing of a warrant exercise, raising $2.3 million in gross proceeds. Existing warrants were exercised to purchase 505,502 shares at a reduced price of $4.60 per share. The company also issued new unregistered warrants for 1,011,004 shares at $4.35 per share. H.C. Wainwright acted as the exclusive placement agent.

The funds will be used for working capital and general corporate purposes, supporting the rollout of SenesTech's Evolve® product line. CEO Joel Fruendt stated that this financing will enable the execution of their plans. The new warrants have not been registered under the Securities Act of 1933 and are subject to certain restrictions.

SenesTech (NASDAQ: SNES) reported record financial results for Q2 2024. Key highlights include:

- Record revenues of $874,000 in H1 2024, up 62% year-over-year
- Q2 2024 revenue of $459,000, a 50% increase from Q2 2023
- Gross margin improved to 54% in Q2 2024, reaching 67% in June
- Smallest quarterly adjusted EBITDA loss in company history
- Evolve™ product line contributed ~60% of YTD revenue
- Expanded distribution through key online retailers and pest management distributors
- Launched Evolve Mouse in May 2024
- Implemented growth initiatives expected to drive H2 performance

The company is progressing towards profitability with reduced cash burn and improved operational metrics.